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a b s t r a c t
In the present work we investigated the neuroprotective role of neuropeptide Y (NPY) after
an excitotoxic insult in rat organotypic hippocampal slice cultures. Exposure of 2 week-old
rat hippocampal slice cultures to 12 mM kainate (KA) for 24 h induced neuronal death in
dentate gyrus (DG) granular cell layer, CA1 and CA3 pyramidal cell layers, as quantified by
cellular propidium iodide (PI) uptake. The activation of Y1 or Y2 receptors 30 min after
starting the exposure to the excitotoxic insult with kainate resulted in neuroprotection by
reducing the PI uptake in DG, CA1 and CA3 cell layers. The use of Y1 or Y2 receptors
antagonists, BIBP3226 (1 mM) or BIIE0246 (1 mM), resulted in the loss of the neuroprotection
induced by the activation of Y1 or Y2 receptors, respectively, in all hippocampal subfields.
Taken together these results suggest that activation of NPY Y1 or Y2 receptors activates
neuroprotective pathways that are able to rescue neurons from excitotoxic cell death.
# 2006 Elsevier Inc. All rights reserved.
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NPY is one of the most abundant and widely distributed
neuropeptides in the mammalian central nervous system and
has been associated with a number of physiological and
pathological conditions [47]. This peptide has been shown to
modulate anxiety, pain, memory, eating behavior, and many
other functions in the central aswell as the peripheral nervous
system [16,47]. Also, the NPY system has been suggested to be
involved in excitation associated with limbic seizures [8].
Six G-protein-coupled NPY receptor subtypes have been
identified (Y1–Y6) and mediate inhibition of cAMP synthesis
[15,24,25]. In the central nervous system, and specifically in* Corresponding author at: Institute of Biochemistry, Faculty of Medic
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doi:10.1016/j.peptides.2006.09.031the hippocampus, Y1 and Y2 receptors are highly expressed
[40]. Y1 receptors are mainly located on dentate granule cells
and hilar NPY-containing interneurons [31], whereas Y2
receptors are expressed at relatively high concentrations in
terminal regions of mossy fibers and Schaffer collaterals [18].
In rats, Y1 receptor antagonists inhibit kainate-induced
seizures and delay kindling epileptogenesis, while a Y1
receptor agonist antagonizes these effects [3,13]. The activa-
tion of Y2 receptors suppresses seizure activity in hippocam-
pal slices in vitro [6,10] and in vivo models [10,45]. Also, NPY,
acting via Y2 receptor, inhibits impulse-dependent synaptic
excitation of CA3 pyramidal cells of the rat hippocampus by
presynaptic mechanisms [28]. Accordingly, the NPY systemine, University of Coimbra, 3004-504 Coimbra, Portugal.
.
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[40,43]. The role of endogenous NPY in regulating seizure
activity [43] is supported by evidence of increased NPY levels
under epileptic conditions in both inhibitory interneurons and
in excitatory granule cells which in control conditions do not
contain the peptide [44,45].
Several in vitro studies have demonstrated that, in the
hippocampus, NPY selectively inhibits glutamatergic synaptic
transmission in mossy fiber CA3 and Schaffer collaterals CA1
pyramidal cell synapses [9,14,19,28] by depressing glutamate
release [14,37] through a mechanism involving the inhibition
of the voltage-dependent Ca2+ influx in presynaptic nerve
terminals [33,36,37]. The control in excess glutamate release,
potentially relevant for hyperexcitability brain disorders, may
contribute to the identified neuroprotection properties of NPY
against excitotoxic injuries [39,40].
In the present work, we identified a post-injury (excito-
toxic) neuroprotective role for NPY that contributes to rescue
injured neurons from cell death.2. Materials and methods
2.1. Rat organotypic hippocampal slice cultures
Organotypic hippocampal slice cultures were prepared using
the interface culture method [41] modified by Kristensen et al.
and Noraberg et al. [21,29]. The 6–8-day-old Wistar rats were
quickly decapitated in accordance with ethically approved
standard procedures (European Community guidelines for the
use of animals in the laboratory), the brains removed under
sterile conditions, and the hippocampi isolated and sectioned
into 350 mm thick slices using a McIlwain tissue chopper.
Slices were placed in cold Gey’s balanced salt solution (GBSS;
Biological Industries, Kibbutz Beit Haemek, Israel) with 25 mM
D-glucose (Merck, Darmstadt, Germany), and all excess tissue
was gently trimmed out. Six individual slices were then
transferred to each porous (0.4 mm) membrane insert (Milli-
pore Corp., Bedford, MA, USA) and inserts placed in a six-well
culture tray (Costar, Corning, NY, USA). Each well contained
1 ml of culture medium, with 50% OPTI-MEM, 25% heat-
inactivated horse serum and 25% Hank’s BSS (HBSS) (all from
Invitrogen, Paisley, UK) and supplemented with D-glucose to a
final concentration of 25 mM. The trays were kept in an
incubator with 5% CO2 and 95% atmospheric air at 36 8C. On
the third day and thereafter the medium was changed to a
chemically defined medium composed of serum-free Neuro-
basal medium (Invitrogen, Paisley, UK) supplemented with
1 mM L-glutamine (Sigma, St Louis, MO) and B-27 supplement
(Invitrogen, Paisley, UK). The medium was changed twice a
week for the next 2 weeks before starting the experiments. No
antimitotic drugs or antibiotics were used at any stage.
2.2. Monitoring propidium iodide uptake
For detection of neuronal cell death, cellular uptake of the
fluorescent dye propidium iodide (PI, 3,8-diamino-5-(3-
(diethylmethylamino)propyl)-6-phenyl phenanthridinium
diiodide; Sigma, St. Louis, MO) was recorded and quantified
according to previously described procedures [21,29]. PI is apolar compound that only enters cells with damaged cell
membranes (dead or dying cells), but once inside the cells, it
binds to DNA, emitting a bright red fluorescence (630 nm)
when exposed to blue-green light (493 nm). PI is basically non-
toxic to neurons [17,22] and has been used as an indicator of
neuronal membrane integrity [17,32] and cell damage [32,46].
Basal level of PI uptakewas determined after adding 2 mMPI to
the medium, and digital fluorescent micrographs were taken
at least 3 h later. The same concentration was also used in all
subsequent medium changes. PI uptake was recorded by
fluorescence microscopy (Axioskop 2 plus, Carl Zeiss, Go¨ttin-
gen, Germany) using a standard rhodamine filter and digital
camera (AxioCam HRc, Carl Zeiss, Go¨ttingen, Germany) with
1000 ms exposure time. After exposing the cultures to the
drugs, digital fluorescent micrographs of the cultures were
taken at different time points during the experiments, for use
in densitometric measurements of the PI uptake in CA1, CA3
pyramidal cell layers and also dentate gyrus (DG), and were
performed by delineating the different subfields using NIH
Image 1.62 analysis software (National Institutes of Health,
Bethesda, MD). The densitometric data were expressed as the
mean value  standard error of mean (S.E.M.). Statistical
analysis was performed using one-way ANOVA followed by
Dunnett’s multiple comparison test. Differences were con-
sidered significant when p < 0.05.
2.3. Exposure to neuropeptide Y receptor agonists/
antagonists
To test the role of NPY receptors in kainate-mediated neuronal
death, cultures were first pre-incubated for 30 or 60 min with
12 mM kainate. This concentration was chosen based on a
concentration-response curve inwhich the EC50 for kainate in
CA1, CA3 and DG was close to 12 mM (data not shown). After
this period, cultures were exposed to the Y1 or Y2 receptor
agonists ([Leu31,Pro34] NPY (1 mM) or NPY13–36 (300 nM),
respectively) (Bachem Bubendorf, Switzerland) for 24 h. The
same experimental protocol was used to study the effect of
1 mM BIBP3226 (Peninsula Laboratories, Belmont, CA) or 1 mM
BIIE0246 (generous gift from Dr. Henri Doods, Boehringer
Ingelheim Pharma, Germany), Y1 and Y2 receptor antagonists,
respectively. These concentrations were chosen based on
previous studies [20,39]. Control cultures were not exposed to
any drug. Digital images of PI uptakewere obtained before any
exposure (day 0) and 24 h after exposure to the NPY receptor
agonists/antagonists (day 1). Basal death (day 0) was sub-
tracted from the values at day 1.
2.4. Evaluation of cell morphology and toluidine blue
staining
Organotypic hippocampal slice cultures were prepared and
stained as described by Noraberg et al. [29]. At the end of each
experiment the cultures were fixed in 4% phosphate buffered
paraformaldehyde (PFA) overnight. Then, cultures were
washed for 1 h in 0.15 M phosphate buffer (25 mM KH2PO4,
125 mMNa2HPO42H2O), and thenwashed in distilledwater for
1 h. After this, the slices were stained with toluidine blue
solution (77 mM Na2HPO42H2O; 67.2 mM citric acid; 3.3 mM
toluidine blue) for 5 min. The slices were washed three times
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96% ethanol (2 min each), washed with distilled water (three
times) and stained once more with toluidine blue solution.
Theywere againwashedwith distilled water (three times) and
dehydrated in 70%, 96% and 99% ethanol (5 min each). After
this, the cultures were detached from the membrane, and
each culture was placed on gelatin-coated glass slides
(cultures from one insert on one glass slide). Finally the
preparations were mounted with Entellan (Merck, Darmstadt,
Germany).3. Results
3.1. Exogenous activation of Y1 and Y2 receptors can
rescue neurons from cell death following the application of
kainate
The putative neuroprotective role of Y1 and Y2 receptors
against kainate receptor-mediated excitotoxicity in CA1 and
CA3 pyramidal cell layers and in DGwas investigated. In theseFig. 1 – The activation of NPY Y1 and NPY Y2 receptor 60 min af
neuronal death in CA1 and CA3 pyramidal cell layers and in DG
12 mM kainate in CA1 (A) and CA3 (B) pyramidal cell layers and i
([Leu31,Pro34] NPY (1 mM), NPY13–36 (300 nM), respectively) on th
induced by 12 mM kainate was set to 100%. Data are shown as m
PI uptake of organotypic hippocampal slice cultures showing th
experimental situation indicated next to each photograph (D): (
exposed to 12 mM kainate, (III) culture exposed to 1 mM [Leu31,P
(IV) culture exposed to 300 nM NPY13–36 60 min after starting texperiments, themean value of PI uptake in all subfields, after
24 h exposure to 12 mM kainate (n = 37), was set to 100%,
representing maximal PI uptake. Basal PI uptake in control
conditions was 47.41  3.94% (n = 49), 40.13  3.93% (n = 49)
and 46.52  3.45% (n = 49) in CA1, CA3 pyramidal cell layers
and DG, respectively.
The activation of Y1 or Y2 receptors for 24 h, by the selective
Y1 or Y2 receptor agonists ([Leu
31,Pro34] NPY (1 mM) or NPY13–
36 (300 nM), respectively) starting at 60 min after the excito-
toxic insult with 12 mM kainate, did not protect neurons from
cell death, resulting in PI uptake similar to that obtained with
kainate alone (Fig. 1).
However, activation (for 24 h) of Y1 receptors with the Y1
receptor agonist [Leu31,Pro34] NPY (1 mM), 30 min after
starting the excitotoxic insult with 12 mM kainate, prevented
neuronal death and reduced the PI uptake to 61.50  6.14%
(n = 36), 53.49  6.37% (n = 36) and 60.20  7.42% (n = 36) in
CA1, CA3 and DG, respectively (Fig. 2). Also, Y2 receptor
activation with the Y2 receptor agonist, NPY13–36 (300 nM),
for 24 h, starting at 30 min after the excitotoxic insult was
neuroprotective and decreased PI uptake to 51.27  5.66%ter starting the insult with kainate (KA) did not prevent the
. Densitometric measurements of PI uptake induced by
n DG (C) showing the effects of Y1 and Y2 receptor agonists
e PI uptake induced by 12 mM kainate. The PI uptake
eans W S.E.M., with n = 12–49. Fluorescent micrographs of
e typical regional pattern of neuronal death induced by the
I) control culture with low basal PI uptake, (II) culture
ro34] NPY 60 min after the exposure to 12 mM kainate and
he exposure to 12 mM kainate.
Fig. 2 – NPY Y1 and NPY Y2 receptor activation 30 min post-kainate (KA) insult prevented cell degeneration in CA1 and CA3
pyramidal cell layers and in DG. Densitometric measurements of PI uptake induced by 12 mM kainate in CA1 (A) and CA3 (B)
pyramidal cell layers and in DG (C) showing the effects of Y1 and Y2 receptor agonists ([Leu
31,Pro34] NPY (1 mM), NPY13–36
(300 nM), respectively) on the PI uptake induced by 12 mMkainate. The PI uptake induced by 12 mM kainate was set to 100%.
Data are shown as meansW S.E.M., with n = 12–49 and *P < 0.05, **P < 0.01 compared to 12 mM kainate using one-way
ANOVA followed by Dunnett’s multiple comparison test. Fluorescent micrographs of PI uptake of organotypic hippocampal
slice cultures showing the typical regional pattern of neuronal death induced by the experimental situation indicated next
to each photograph (D): (I) control culture with low basal PI uptake, (II) culture exposed to 12 mM kainate, (III) culture
exposed to 1 mM [Leu31,Pro34] NPY 30min after starting the exposure to 12 mM kainate and (IV) culture exposed to 300 nM
NPY13–36 30 min after starting the exposure to 12 mM kainate.
p e p t i d e s 2 8 ( 2 0 0 7 ) 2 8 8 – 2 9 4 291(n = 30), 54.78  4.10% (n = 30) and 39.40  4.44% (n = 30) in
CA1, CA3 and DG (Fig. 2).
Evaluation ofmorphology in toluidine blue stained cultures
exposed to 12 mM kainate for 24 h indicated strong degen-
erative changes, especially in the CA3 pyramidal cell layer,
wheremany swollen neuronswith a necrotic-likemorphology
and condensed apoptotic-like nuclei were observed (Fig. 3B).
These degenerative eventswere prevented followingY1 andY2
receptor activation 30 min after starting the kainate exposure
(Fig. 3C and D).
The selectivity of the effects observed in the presence of
NPY Y1 and Y2 receptor agonists was further evaluated by
using BIBP3226 or BIIE0246 (Y1 or Y2 receptor antagonist,
respectively). The co-exposure to BIBP3226 (1 mM) and [Leu31,-
Pro34] NPY (1 mM) 30 min after starting the exposure to 12 mM
kainate resulted in the loss of the neuroprotection caused by
the activation of Y1 receptors: 84.29  15.34% (n = 12) in CA1,
116.30  16.75% (n = 12) in CA3 and 115.5  21.19% (n = 12) in
DG (Fig. 4). Similarly, co-exposure to BIIE0246 (1 mM) andNPY13-36 (300 nM) resulted in inhibition of the neuroprotec-
tive effects induced by activation of Y2 receptors in all
hippocampal subregions analyzed: 105.30  14.85% (n = 12)
in CA1, 96.87  18.13% (n = 12) in CA3 and 102.10  25.72%
(n = 12) in DG (Fig. 4).4. Discussion
We have previously shown that pre-incubation with NPY
receptor agonists, before starting an excitotoxic insult with
kainate, resulted in neuroprotection against kainate-
induced excitotoxicity in rat organotypic hippocampal slice
cultures [39]. In the present study we attempted to
determine whether NPY receptor activation after starting
the excitotoxic insult with kainate can still protect
and rescue neurons from cell death. Here we show that,
indeed, NPY Y1 and Y2 receptor activation at 30 min but not
60 min after starting kainate exposure prevents cell death
Fig. 3 – Morphological changes of cultured organotypic hippocampal slice cultures exposed to kainate (KA) for 24 h and
neuroprotection afforded by NPY receptor agonists. (A) toluidine blue stained hippocampal slice cultures in control
condition, (B) culture exposed to 12 mM kainate, (C) culture incubated with the Y1 receptor agonist ([Leu
31,Pro34] NPY (1 mM)
30 min after starting the exposure to 12 mM kainate and (D) culture incubated with the Y2 receptor agonist NPY13–36
(300 nM) after starting the exposure to 12 mM kainate. Arrow indicates swollen necrotic-like cells; arrow head indicate
condensed apoptotic-like cell nuclei. Scale bar 40 mm.
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cells.
In accordance with published reports [12,39], kainate
exposure results in both necrotic and apoptotic-like fea-
tures. Necrosis is characterized by progressive loss of
cytoplasmic integrity, rapid influx of Na+, Ca2+, and water,
resulting in cytoplasmic swelling and nuclear pyknosis
[2,4,27]. The latter feature leads to nuclear and cell
fragmentation and the release of lysosomal and granular
contents into surrounding extracellular space, causing
subsequent inflammation [7,26,30,35]. Apoptosis can be
induced by the ligation of plasma membrane death
receptors (CD95, TNF-receptor, and TNF-related apoptosis-
inducing ligand receptor), which stimulate the ‘‘extrinsic
pathway’’, or by perturbation of intracellular environment
homeostasis, the ‘‘intrinsic pathway’’ [5,11]. The intrinsic
pathway involves mitochondrial dysfunction and the
release of mitochondrial membrane proteins including
cytochrome c, which stimulates cytosolic assembly of the
apoptosome, the caspase activation complex [5,11,23].
Mitochondria participate in apoptotic and necrotic celldeath, suggesting that death/toxic signals, through common
mechanisms, can cause both apoptosis and necrosis
depending on variables such as ATP content [5].
Since NPY receptors activate signaling pathways
involved in the regulation of intracellular Ca2+ homeostasis
[38], it is possible that NPY may exert its protective effects
partially via its action on Ca2+ influx, as Thiriet et al. [42]
suggested for NPY-mediated protection against metham-
phetamine-induced neuronal apoptosis. This idea is
consistent with the demonstration that activation of both
Y1 and Y2 receptors in hippocampal cells inhibits the
increase in intracellular calcium concentration following
KCl depolarization [36,38]. Also, by inhibiting Ca2+
influx NPY may inhibit the calcium-dependent death path-
ways involving caspase and calpain activation and mito-
chondrial dysfunction [1,34], and thus prevent cell death
[39].
Taken together, the present data further support a putative
role for NPY-dependent signaling mechanisms as potential
neuroprotective targets against excitotoxic insults, able to
rescue post-insult injured neurons.
Fig. 4 – Blockade of Y1 and Y2 receptor-mediated neuroprotection by Y1 and Y2 selective antagonists. Effect of 1 mM BIBP3226
or 1 mM BIIE0246 (Y1 and Y2 receptor antagonists, respectively) on PI uptake induced by 12 mM kainate plus [Leu
31,Pro34]
NPY (1 mM) or NPY13–36 (300 nM) (Y1 and Y2 receptor agonist, respectively) in the CA1 (A) and CA3 (B) pyramidal cell layers
and in DG (C). Data are shown as means W S.E.M., with n = 12–49 and *P < 0.05, **P < 0.01 compared to the effect of 12 mM
kainate, using one-way ANOVA followed by Dunnett’s multiple comparison test.
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